Innovative Industrial Properties (IIPR) Q2 FY26 earnings call: the analyst Q&A

IIPR fully funded its $270 million commitment to IQHQ, deploying the remaining $120 million this quarter. This investment, initiated in August 2025, is part of the company's strategy to diversify its portfolio into the life sciences sector. The latest commitment is expected to generate a yield greater than 14%. IQHQ has reported significant leasing activity, including a long-term lease with Advanced Cell for a 128,000 square foot building at Innovation Park and a 244,000 square foot lease with Lila Sciences at Alewife Park, totaling 372,000 square feet of gross leasing activity across these two assets since IIPR's initial investment.

The company completed new leases totaling 389,000 square feet across five properties in California, Illinois, and Ohio during the first half of the year. Additionally, agreements are in place for 488,000 square feet across four assets previously leased to Forefront Ventures. The average total leasing costs for these 877,000 square feet of gross leasing activity are estimated to be less than $5 per square foot. Management noted ongoing interest in the two Florida properties (593,000 sq ft) previously leased by Parallel, which defaulted on its obligations.

IIPR proactively strengthened its balance sheet by completing nearly $150 million in secured term loan financings and addressing a $291 million senior debt maturity in May. The company also raised $35 million through its common stock ATM program and $21 million through its preferred stock ATM program. A significant capital markets event was the upsized $402.5 million exchangeable notes offering due 2029, priced at an attractive 6%. In connection with this, IIPR repurchased approximately $80.5 million of its common stock. These actions resulted in $300 million in total liquidity at quarter-end, consisting of cash on hand and revolving credit facility availability.

The company continued its strategy of opportunistically monetizing select assets. During the quarter, IIPR closed on an $88.5 million sale of a 389,000 square foot facility in New York to Vireo Growth, receiving a $39 million down payment and providing $49 million in seller financing at a 15% interest rate. A land site in San Marcos, Texas, was also sold. Two retail properties in Michigan and California are under contract for sale, and a dispensary property in Arizona was sold earlier in the year, reflecting a focus on recycling capital across the portfolio.

Progress on federal cannabis reform continued, with the DEA completing its hearing on the proposed rescheduling of marijuana from Schedule 1 to Schedule 3. While timing for final action remains uncertain, this represents a meaningful step forward. The capital markets are beginning to reflect this progress, with Trulieve becoming the first U.S. cannabis operator to list on the NYSE, and other operators like Curaleaf, Verano, and Ascend Wellness taking steps towards potential uplistings, which could expand the industry's institutional investor base.

Encouraging signs were observed in the broader life sciences market. Q1 leasing activity across major U.S. markets increased to approximately 3 million square feet, exceeding the 2025 quarterly average. Venture capital funding rose 12% year-over-year to $7.4 billion. Despite elevated vacancy, the development pipeline is down over 85% from its 2023 peak, with approximately 72% of pending new supply already pre-leased, leaving less than 1% of total existing inventory as unleased supply.